MovDisordV3, PascalFrancis, Corpus, bibRecord, 003346

Cabergoline in Parkinson's disease complicated by motor fluctuations

Identifieur interne : 003346 ( PascalFrancis/Corpus ); précédent : 003345; suivant : 003347

Cabergoline in Parkinson's disease complicated by motor fluctuations

Auteurs : G. Geminiani ; V. Fetoni ; S. Genitrini ; P. Giovannini ; F. Tamma ; T. Caraceni

Source :

Movement disorders [ 0885-3185 ] ; 1996.

RBID : Pascal:96-0423269

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Cabergoline, Chimiothérapie, Antiparkinsonien, Stimulant dopaminergique, Ergot dérivé, Trouble moteur, Efficacité traitement, Traitement, Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Dopamine agonist, Ergot derivatives, Human, Motor system disorder, Parkinson disease, Treatment, Treatment efficiency.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 11`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Cabergoline in Parkinson's disease complicated by motor fluctuations`
A11	`01`	`1`		`@1 GEMINIANI (G.)`
A11	`02`	`1`		`@1 FETONI (V.)`
A11	`03`	`1`		`@1 GENITRINI (S.)`
A11	`04`	`1`		`@1 GIOVANNINI (P.)`
A11	`05`	`1`		`@1 TAMMA (F.)`
A11	`06`	`1`		`@1 CARACENI (T.)`
A14	`01`			`@1 Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute @2 Milan @3 ITA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 495-500`
A21				`@1 1996`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000064078610030`
A44				`@0 0000 @1 © 1996 INIST-CNRS. All rights reserved.`
A45				`@0 11 ref.`
A47	`01`	`1`		`@0 96-0423269`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Cabergoline @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 06`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 06`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 06`
C03	`05`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 07`
C03	`05`	`X`	`ENG`	`@0 Dopamine agonist @5 07`
C03	`05`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 07`
C03	`06`	`X`	`FRE`	`@0 Ergot dérivé @5 08`
C03	`06`	`X`	`ENG`	`@0 Ergot derivatives @5 08`
C03	`06`	`X`	`SPA`	`@0 Ergot derivado @5 08`
C03	`07`	`X`	`FRE`	`@0 Trouble moteur @5 10`
C03	`07`	`X`	`ENG`	`@0 Motor system disorder @5 10`
C03	`07`	`X`	`SPA`	`@0 Trastorno motor @5 10`
C03	`08`	`X`	`FRE`	`@0 Efficacité traitement @5 17`
C03	`08`	`X`	`ENG`	`@0 Treatment efficiency @5 17`
C03	`08`	`X`	`SPA`	`@0 Eficacia tratamiento @5 17`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 18`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 18`
C03	`09`	`X`	`GER`	`@0 Aufbereiten @5 18`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 18`
C03	`10`	`X`	`FRE`	`@0 Homme @5 20`
C03	`10`	`X`	`ENG`	`@0 Human @5 20`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 62`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 62`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 62`
N21				`@1 288`

Format Inist (serveur)

NO :	PASCAL 96-0423269 INIST
ET :	Cabergoline in Parkinson's disease complicated by motor fluctuations
AU :	GEMINIANI (G.); FETONI (V.); GENITRINI (S.); GIOVANNINI (P.); TAMMA (F.); CARACENI (T.)
AF :	Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute/Milan/Italie (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1996; Vol. 11; No. 5; Pp. 495-500; Bibl. 11 ref.
LA :	Anglais
CC :	002B02B06
FD :	Parkinson maladie; Cabergoline; Chimiothérapie; Antiparkinsonien; Stimulant dopaminergique; Ergot dérivé; Trouble moteur; Efficacité traitement; Traitement; Homme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique
ED :	Parkinson disease; Chemotherapy; Antiparkinson agent; Dopamine agonist; Ergot derivatives; Motor system disorder; Treatment efficiency; Treatment; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder
GD :	Aufbereiten
SD :	Parkinson enfermedad; Quimioterapia; Antiparkinsoniano; Estimulante dopaminérgico; Ergot derivado; Trastorno motor; Eficacia tratamiento; Tratamiento; Hombre
LO :	INIST-20953.354000064078610030
ID :	96-0423269

Links to Exploration step

Pascal:96-0423269

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cabergoline in Parkinson's disease complicated by motor fluctuations</title>
<author><name sortKey="Geminiani, G" sort="Geminiani, G" uniqKey="Geminiani G" first="G." last="Geminiani">G. Geminiani</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fetoni, V" sort="Fetoni, V" uniqKey="Fetoni V" first="V." last="Fetoni">V. Fetoni</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Genitrini, S" sort="Genitrini, S" uniqKey="Genitrini S" first="S." last="Genitrini">S. Genitrini</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Giovannini, P" sort="Giovannini, P" uniqKey="Giovannini P" first="P." last="Giovannini">P. Giovannini</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tamma, F" sort="Tamma, F" uniqKey="Tamma F" first="F." last="Tamma">F. Tamma</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Caraceni, T" sort="Caraceni, T" uniqKey="Caraceni T" first="T." last="Caraceni">T. Caraceni</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">96-0423269</idno>
<date when="1996">1996</date>
<idno type="stanalyst">PASCAL 96-0423269 INIST</idno>
<idno type="RBID">Pascal:96-0423269</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003346</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cabergoline in Parkinson's disease complicated by motor fluctuations</title>
<author><name sortKey="Geminiani, G" sort="Geminiani, G" uniqKey="Geminiani G" first="G." last="Geminiani">G. Geminiani</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fetoni, V" sort="Fetoni, V" uniqKey="Fetoni V" first="V." last="Fetoni">V. Fetoni</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Genitrini, S" sort="Genitrini, S" uniqKey="Genitrini S" first="S." last="Genitrini">S. Genitrini</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Giovannini, P" sort="Giovannini, P" uniqKey="Giovannini P" first="P." last="Giovannini">P. Giovannini</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tamma, F" sort="Tamma, F" uniqKey="Tamma F" first="F." last="Tamma">F. Tamma</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Caraceni, T" sort="Caraceni, T" uniqKey="Caraceni T" first="T." last="Caraceni">T. Caraceni</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1996">1996</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dopamine agonist</term>
<term>Ergot derivatives</term>
<term>Human</term>
<term>Motor system disorder</term>
<term>Parkinson disease</term>
<term>Treatment</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Cabergoline</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Stimulant dopaminergique</term>
<term>Ergot dérivé</term>
<term>Trouble moteur</term>
<term>Efficacité traitement</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>11</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Cabergoline in Parkinson's disease complicated by motor fluctuations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GEMINIANI (G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FETONI (V.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GENITRINI (S.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GIOVANNINI (P.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>TAMMA (F.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>CARACENI (T.)</s1>
</fA11>
<fA14 i1="01"><s1>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>495-500</s1>
</fA20>
<fA21><s1>1996</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000064078610030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1996 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>11 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>96-0423269</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Trouble moteur</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Motor system disorder</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Trastorno motor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>62</s5>
</fC07>
<fN21><s1>288</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 96-0423269 INIST</NO>
<ET>Cabergoline in Parkinson's disease complicated by motor fluctuations</ET>
<AU>GEMINIANI (G.); FETONI (V.); GENITRINI (S.); GIOVANNINI (P.); TAMMA (F.); CARACENI (T.)</AU>
<AF>Centre for the Study and Treatment of Parkinson's Disease and Extrapyramidal Disorders, "C. Besta" National Neurological Institute/Milan/Italie (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1996; Vol. 11; No. 5; Pp. 495-500; Bibl. 11 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Cabergoline; Chimiothérapie; Antiparkinsonien; Stimulant dopaminergique; Ergot dérivé; Trouble moteur; Efficacité traitement; Traitement; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique</FG>
<ED>Parkinson disease; Chemotherapy; Antiparkinson agent; Dopamine agonist; Ergot derivatives; Motor system disorder; Treatment efficiency; Treatment; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Quimioterapia; Antiparkinsoniano; Estimulante dopaminérgico; Ergot derivado; Trastorno motor; Eficacia tratamiento; Tratamiento; Hombre</SD>
<LO>INIST-20953.354000064078610030</LO>
<ID>96-0423269</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003346 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003346 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:96-0423269
   |texte=   Cabergoline in Parkinson's disease complicated by motor fluctuations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Cabergoline in Parkinson's disease complicated by motor fluctuations

Cabergoline in Parkinson's disease complicated by motor fluctuations

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri